- Home
- PRMB vs PCVX Comparison
PRMB vs PCVX Comparison
Compare PRMB & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRMB | PCVX |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRMB | PCVX |
|---|---|---|
| Price | $23.09 | $59.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $28.40 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 5.1M | 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $28.09 |
| 52 Week High | $35.85 | $76.61 |
Technical Indicators
Market Signals| Indicator | PRMB | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 80.56 | 59.15 |
| Support Level | $22.64 | $42.30 |
| Resistance Level | $25.32 | N/A |
| Average True Range (ATR) | 0.78 | 3.27 |
| MACD | 0.43 | 0.14 |
| Stochastic Oscillator | 94.55 | 62.30 |
Price Performance
Historical ComparisonAbout PRMB Primo Brands Corporation
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.